Evidence map›Paper›PMID 32559067›Full record

ArticleACS chemical neuroscience2020

Classics in Neuroimaging: Imaging the Endocannabinoid Pathway with PET.

Cassis Varlow, Isabelle Boileau, Hsiao-Ying Wey, Steven H Liang, Neil Vasdev

Open access · greenAbstract read
In one paragraph

Article in ACS chemical neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Quantification of [Frontiers in neuroscience · 2026
    Article
  3. Fatty acid amide hydrolase in major depressive episodes: A [Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  4. Article
  5. Cannabis use disorder: from neurobiology to treatment.The Journal of clinical investigation · 2024
    Review
  6. Review
  7. Article
  8. Article
  9. Cannabis use and cannabis use disorder.Nature reviews. Disease primers · 2021
    Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Cassis VarlowAzrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario M5T-1R8, Canada.
Isabelle BoileauAzrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario M5T-1R8, Canada.
Hsiao-Ying WeyAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, United States.
Steven H LiangDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, United States.ORCID 0000-0003-1413-6315
Neil VasdevAzrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario M5T-1R8, Canada.ORCID 0000-0002-2087-5125
Centre for Addiction and Mental Health · CAHarvard University · US

Funding

Translation of tau-selective PET radiopharmaceuticals in Alzheimers patientsR01AG052414 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI PRICE, JULIE C, VASDEV, NEIL · 2018 to 2021
$2.7M
Neuro-PET Radiotracer Discovery for Imaging Glycogen Synthase Kinase-3R01AG054473 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI VASDEV, NEIL · 2017 to 2020
$1.7M
New PET tracers for neuroimaging of FAAH in endocannabinoid signalingK01DA038000 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LIANG, STEVEN H · 2014 to 2018
$927k
Novel PET Tracers for Imaging Monoacylglycerol Lipase in Endocannabinoid SignalingR33DA043507 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LIANG, STEVEN H · 2019 to 2021
$851k
Novel PET Tracers for Imaging Monoacylglycerol Lipase in Endocannabinoid SignalingR21DA043507 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LIANG, STEVEN H · 2017 to 2018
$425k
NIA NIH HHS R01 AG052414NIA NIH HHS R01 AG054473NIDA NIH HHS K01 DA038000NIDA NIH HHS R21 DA043507NIDA NIH HHS R33 DA043507
6 · The paper itself

Abstract

This Viewpoint aims to highlight positron emission tomography (PET) research studies that have shaped our understanding of the endocannabinoid system (ECS) through radiopharmaceutical targeting of cannabinoid receptors 1 and 2 (CB

Indexed as

EndocannabinoidsMonoacylglycerol LipasesAmidohydrolasesBrainEnzyme InhibitorsPositron-Emission TomographyRadiochemistryReceptor, Cannabinoid, CB1AmidohydrolasesEndocannabinoidsEnzyme InhibitorsMonoacylglycerol LipasesReceptor, Cannabinoid, CB1CB1CB2endocannabinoidFAAHMAGLPET

Identifiers

PMID32559067
PMCPMC9105826
OpenAlexW3036032624

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.